FGAM
BLPH

Financial Gravity Asset Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Financial Gravity Asset Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$18 – 1844
2023
Q2 		$18 Buy
+1
New +$6 ﹤0.01% 1499
2023
Q1 		– Sell
-1
Closed -$50 – 1766
2022
Q4 		$50 Buy
+1
New +$1 ﹤0.01% 1232

Other funds holding BLPH

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Financial Gravity Asset Management's BLPH Position: Q3 2023 in Review

Financial Gravity Asset Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2023, closing a stake of 1 share — an estimated $18 sold.

Financial Gravity Asset Management first reported a position in BLPH in Q4 2022 and held it in 2 quarters. The position peaked at $50 in Q4 2022. 22 funds tracked by Wall St. Rank hold BLPH as of Q3 2023.

  • Financial Gravity Asset Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Bellerophon Therapeutics, Inc. share in Q3 2023, an estimated $18.
  • Financial Gravity Asset Management first reported a position in Bellerophon Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
  • Financial Gravity Asset Management's Bellerophon Therapeutics, Inc. position peaked at $50 in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2023.

Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.